You are here
Future Opportunities in Transplant Diagnostics Market
The report studies the global transplant diagnostics market over the forecast period of 2018 to 2023. The market is projected to reach USD 4.91 billion by 2023 from USD 3.44 billion in 2018, at a CAGR of 7.4%.
Browse 122 market data Tables and 47 Figures spread through 221 Pages and in-depth TOC on "Transplant Diagnostics Market by Technology (PCR, NGS, Sanger Sequencing), Product (Instrument, Reagent, Software), Application (HLA, Blood Profile, Pathogen Detection), Type (Heart, Kidney, Liver, Stem Cell), End User (Hospital) – Global Forecast to 2023"
Based on product, the reagents and consumables segment is estimated to have the largest share of the market in 2018.
On the basis of product, the transplant diagnostics market is segmented into reagents & consumables, instruments, and software & services. The reagents & consumables segment is expected to account for the largest share of the global transplant diagnostics market in 2018. Factors such as the increasing patient emphasis on effective and early patient profiling during organ transplantation, and growing adoption of transplant diagnostic techniques in related research studies are driving the growth of this segment.
Based on technology, the molecular assays segment is expected to witness the highest growth during the forecast period.
On the basis of technology, the transplant diagnostics market is segmented into molecular assay and non-molecular assay technology. The molecular assay technology segment is expected to register the highest CAGR during the forecast period. Factors such as its varied applications in patient profiling, rising public-private investments to support product development, and increasing clinical evidence to establish clinical efficacy of molecular assay techniques are driving the growth of this segment.
PDF Download : https://www.marketsandmarkets.com/pdfdownload.asp?id=2531061
Based on transplant type, the solid organ transplantation segment is expected to account for the largest share of this market in 2018.
On the basis of transplant type, the transplant diagnostics market is categorized into solid organ, stem cell, and soft tissue transplantation. Solid organ transplantation is expected to account for the largest share of the transplant diagnostics market in 2018. The supportive government regulations to increase organ donations across major healthcare markets, rising number of chronic diseases/disorders that leads to transplantation, and ongoing technological advancements in the field of transplant diagnostics are the key factors supporting the growth of the transplant diagnostics market for solid organ transplantation.
North America is expected to dominate the transplant diagnostics market in 2018.
Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The large share of North America can be attributed to the continuous commercialization of innovative transplant diagnostic products coupled with ongoing advancements in the field of genomics and proteomics, recent discovery genetic biomarkers & their clinical role in immunoassay testing, and increasing prevalence of chronic and communicable diseases.
Major players operating in the market include Bio-Rad Laboratories, Inc. (US), F. Hoffman-La Roche Ltd. (Switzerland), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (US), and bioMérieux S.A. (France). Other prominent players present in this market are Immucor, Inc. (US), Illumina, Inc. (US), Luminex Corporation (US), CareDx (US), Becton, Dickinson and Company (US), Hologic (US), and GenDx (Netherlands).
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.